Performance of KYMR Kymera Therapeutics | 102.4% in 12m

Compare KYMR with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?

Compare Kymera Therapeutics with its related Sector/Index XBI

Compare Kymera Therapeutics with its related Sector/Index XBI

Performance Duell KYMR vs XBI

TimeFrame KYMR XBI
1 Day -6.49% -2.26%
1 Week 12.3% -0.43%
1 Month 40.4% 8.88%
3 Months 24.7% 16.99%
6 Months 61.0% 12.18%
12 Months 102.4% 14.95%
YTD 72.8% 8.24%
Rel. Perf. 1m 2.36
Rel. Perf. 3m 0.70
Rel. Perf. 6m 3.06
Rel. Perf. 12m 3.06

Is Kymera Therapeutics a good stock to buy?

No, based on ValueRay Fundamental Analyses, Kymera Therapeutics (NASDAQ:KYMR) is currently (July 2024) a stock to sell. It has a ValueRay Fundamental Rating of -58.76 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KYMR as of July 2024 is 50.05. This means that KYMR is currently undervalued and has a potential upside of +14.27% (Margin of Safety).

Is KYMR a buy, sell or hold?

  • Strong Buy: 8
  • Buy: 3
  • Hold: 6
  • Sell: 0
  • Strong Sell: 0
Kymera Therapeutics has received a consensus analysts rating of 4.12. Therefor, it is recommend to buy KYMR.
Values above 0%: KYMR is performing better - Values below 0%: KYMR is underperforming

Compare KYMR with Broad Market Indices

Symbol 1w 1m 6m 12m
US S&P 500 SPY 13.00% 39.29% 44.31% 78.47%
US NASDAQ 100 QQQ 14.84% 41.40% 44.59% 73.87%
US Dow Jones Industrial 30 DIA 10.02% 35.63% 51.56% 84.84%
German DAX 40 DBXD 13.24% 39.16% 50.71% 91.08%
UK FTSE 100 ISFU 12.15% 37.88% 46.52% 90.85%
Shanghai Shenzhen CSI 300 CSI 300 11.60% 41.16% 53.30% 110.44%
Hongkong Hang Seng HSI 12.37% 42.34% 59.78% 118.05%
Japan Nikkei 225 EXX7 16.39% 38.16% 56.61% 93.34%
India NIFTY 50 INDA 11.85% 37.43% 44.59% 73.57%
Brasil Bovespa EWZ 15.32% 36.61% 72.89% 111.44%

KYMR Kymera Therapeutics vs. Sectors

Symbol 1w 1m 6m 12m
Communication Services XLC 13.58% 38.37% 44.62% 70.65%
Consumer Discretionary XLY 12.06% 35.37% 51.16% 90.69%
Consumer Staples XLP 10.70% 38.89% 50.98% 95.74%
Energy XLE 8.88% 34.18% 42.27% 87.91%
Financial XLF 9.82% 35.07% 44.17% 77.51%
Health Care XLV 12.47% 39.16% 54.68% 92.67%
Industrial XLI 10.62% 38.07% 47.91% 85.93%
Materials XLB 10.88% 38.35% 49.43% 91.63%
Real Estate XLRE 10.14% 33.90% 53.41% 93.54%
Technology XLK 15.48% 43.25% 45.96% 74.02%
Utilities XLU 13.29% 38.34% 44.43% 96.57%
Aerospace & Defense XAR 10.92% 37.47% 48.25% 82.97%
Biotech XBI 12.74% 31.50% 48.85% 87.45%
Homebuilder XHB 6.86% 32.73% 41.89% 64.97%
Retail XRT 12.35% 39.36% 48.39% 84.89%

KYMR Kymera Therapeutics vs. Commodities

Symbol 1w 1m 6m 12m
Oil USO 13.59% 38.82% 45.33% 86.59%
Natural Gas UNG 19.60% 69.62% 97.59% 153.88%
Gold GLD 11.18% 35.60% 40.53% 78.47%
Silver SLV 17.47% 39.49% 30.32% 81.89%
Copper CPER 17.46% 44.53% 47.70% 89.79%

Returns of KYMR vs. Yields & Bonds

Symbol 1w 1m 6m 12m
iShares 20+ Years Bond TLT 12.38% 41.25% 59.38% 106.91%
iShares High Yield Corp. Bond HYG 11.98% 38.96% 56.55% 92.41%
Does Kymera Therapeutics outperform its market, is KYMR a Sector Leader?
Yes, over the last 12 months Kymera Therapeutics (KYMR) made 102.40%, while its related Sector, the SPDR S&P Biotech (XBI) made 14.95%.
Over the last 3 months KYMR made 24.72%, while XBI made 16.99%.
Period KYMR XBI S&P 500
1 Month 40.38% 8.88% 1.09%
3 Months 24.72% 16.99% 11.00%
12 Months 102.40% 14.95% 23.93%